LCL161_COA_16169_MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jan.-07-2019Print Date:Jan.-07-20191. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :CIL56Catalog No. :HY-112063CAS No. :300802-28-21.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4), H302Acute aquatic toxicity (Category 1), H400Chronic aquatic toxicity (Category 1), H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word No data availableHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effectsPrecautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor ⁄ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents ⁄ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C23H27N3O5S2Molecular Weight:489.61CAS No. :300802-28-24. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077 Class: 9 Packing group: III EMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutantIATAUN number: 3077 Class: 9 Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis)reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:Acute Health Hazard16. OTHER INFORMATIONCopyright 2019 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

0843PAGE 1 OF 24LIQUID ASSAYED CHEMISTRY CONTROL PREMIUM PLUS - LEVEL 1 (LIQ CHEM ASY PREMIUM PLUS 1)Cat. No . LAL 4213 Lot No . 153UL Size : 12 x 5 ml Expiry : 2015-02INTENDED USEThis product is intended for in vitro diagnostic use, in the quality control of diagnostic assays. The Liquid Assayed Chemistry Control Premium Plus is for the control of accuracy.DEVICE DESCRIPTIONThe Liquid Assayed Chemistry Control Premium Plus is supplied at 3 levels, level 1, 2 and 3. Target values and ranges are supplied for the analytes listed in the values section at all three levels.SAFETY PRECAUTIONS AND WARNINGSFor in vitro diagnostic use only. Do not pipette by mouth. Exercise the normal precautions required for handling laboratory reagents.Human source material from which this product has been derived has been tested at donor level for the Human Immunodeficiency Virus (HIV 1, HIV 2) antibody, Hepatitis B Surface Antigen (HbsAg), and Hepatitis C Virus (HCV) antibody and found to be NON-REACTIVE. FDA approved methods have been used to conduct these tests.However, since no method can offer complete assurance as to the absence of infectious agents, this material and all patient samples should be handled as though capable of transmitting infectious diseases and disposed of accordingly.Health and Safety Data Sheets are available on request.STORAGE AND STABILITY OPENED: Store refrigerated (+2ºC to + 8ºC). Thawed serum is stable for 7 days at +2ºC to +8ºC, with the followingexceptions: Troponin T is stable for 3 days at +2ºC to +8ºC. Only the required amount of product should be removed. After use, any residual product should NOT BE RETURNED to the original vial.UNOPENED: Store frozen at -20ºC to -70ºC. Stable to expiration date printed on individual vials (see Limitations).LIMITATIONSFor Total Acid Phosphatase, the material should be stabilised by adding 1 drop (25 µl – 30 µl) of 0.7M Acetic acid solution to 1ml of the serum after thawing. After stabilisation, Total Acid Phosphatase is stable for 7 days at +2ºC to +8ºC. Bilirubin in the serum is light sensitive and it is recommended that the serum is stored in the dark.ALT, Total Acid Phosphatase, Alkaline Phosphatase, Total and Direct Bilirubin values may gradually decrease during the products shelf life.Bacterial contamination of the thawed serum will cause reductions in the stability of many components. The control should not be used as a calibration material.PREPARATION1. Allow the frozen control to thaw at room temperature (+15ºC to +25ºC) until completely thawed. Swirl the contents to ensurehomogeneity.2. Refer to the Control section of the individual analyser application.3. Refrigerate any unused material. Prior to reuse, mix contents thoroughly.MATERIALS PROVIDEDLiquid Assayed Chemistry Control Premium Plus - Level 1 12 x 5 mlMATERIALS REQUIRED BUT NOT PROVIDED NoneASSIGNED VALUESEach lot of serum is submitted to a number of external laboratories. Values are assigned from a consensus of results obtained by these laboratories and internal testing conducted at Randox Laboratories Ltd. With each batch, a control range is provided for individual parameters and each parameter method.If an instrument specific value is not available, refer to the Mean of all Instruments section. If necessary, contact Randox Laboratories – Customer Technical Services, Northern Ireland, Tel: +44 (0) 28 9445 1070 or email Technical.Services@29 Nov 13 rwPage 2 of 2429/11/2013___________________________________________________________________________________________________RANDOX Laboratories Ltd., 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QYTel: +44 (0) 28 9442 2413 Fax: +44 (0) 28 9445 2912Email: applications@ Website: Page 3 of 24 29/11/2013___________________________________________________________________________________________________RANDOX Laboratories Ltd., 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QYTel: +44 (0) 28 9442 2413 Fax: +44 (0) 28 9445 2912Email: applications@ Website: Page 4 of 24 29/11/2013___________________________________________________________________________________________________RANDOX Laboratories Ltd., 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QYTel: +44 (0) 28 9442 2413 Fax: +44 (0) 28 9445 2912Email: applications@ Website: Page 5 of 2429/11/2013___________________________________________________________________________________________________RANDOX Laboratories Ltd., 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QYTel: +44 (0) 28 9442 2413 Fax: +44 (0) 28 9445 2912Email: applications@ Website: Page 6 of 2429/11/2013___________________________________________________________________________________________________RANDOX Laboratories Ltd., 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QYTel: +44 (0) 28 9442 2413 Fax: +44 (0) 28 9445 2912Email: applications@ Website: Page 7 of 2429/11/2013___________________________________________________________________________________________________RANDOX Laboratories Ltd., 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QYTel: +44 (0) 28 9442 2413 Fax: +44 (0) 28 9445 2912Email: applications@ Website: Page 8 of 2429/11/2013___________________________________________________________________________________________________RANDOX Laboratories Ltd., 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QYTel: +44 (0) 28 9442 2413 Fax: +44 (0) 28 9445 2912Email: applications@ Website: Page 9 of 2429/11/2013___________________________________________________________________________________________________RANDOX Laboratories Ltd., 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QYTel: +44 (0) 28 9442 2413 Fax: +44 (0) 28 9445 2912Email: applications@ Website: Page 10 of 2429/11/2013___________________________________________________________________________________________________RANDOX Laboratories Ltd., 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QYTel: +44 (0) 28 9442 2413 Fax: +44 (0) 28 9445 2912Email: applications@ Website: Page 11 of 2429/11/2013___________________________________________________________________________________________________Page 12 of 2429/11/2013___________________________________________________________________________________________________Page 13 of 2429/11/2013___________________________________________________________________________________________________Page 14 of 2429/11/2013___________________________________________________________________________________________________Page 15 of 2429/11/2013___________________________________________________________________________________________________Page 16 of 2429/11/2013___________________________________________________________________________________________________Page 17 of 2429/11/2013___________________________________________________________________________________________________Page 18 of 2429/11/2013___________________________________________________________________________________________________Page 19 of 2429/11/2013___________________________________________________________________________________________________Page 20 of 2429/11/2013___________________________________________________________________________________________________Page 21 of 2429/11/2013___________________________________________________________________________________________________Page 22 of 2429/11/2013___________________________________________________________________________________________________Page 23 of 2429/11/2013___________________________________________________________________________________________________Page 24 of 2429/11/2013___________________________________________________________________________________________________。

线粒体呼吸链复合体Ⅳ/细胞色素C 氧化酶活性检测试剂盒说明书微量法注意：本产品试剂有所变动，请注意并严格按照该说明书操作。

货号：BC0945规格：100T/96S产品组成：使用前请认真核对试剂体积与瓶内体积是否一致，有疑问请及时联系索莱宝工作人员。

试剂名称规格 保存条件 提取液液体75 mL×2瓶 2-8℃保存 试剂一液体33mL×1瓶 2-8℃保存 试剂二粉剂×2瓶 -20℃保存 试剂三粉剂×2支 2-8℃保存溶液的配制：1、 试剂二：试剂放于试剂瓶内玻璃瓶中。

临用前取1支加入13.5mL 试剂一溶解，用不完的试剂-20℃分装保存2周，避免反复冻融；2、 试剂三：试剂置于试剂瓶内EP 管中；临用前取1支加入2mL 试剂一溶解，用不完的试剂-20℃保存2周，避免反复冻融；3、 工作液的配制：临用前取0.5mL 试剂三加入到溶解好的4.5mL 试剂二中混合备用（约25T ），或者按比例现用现配。

产品说明：线粒体复合体Ⅳ又称细胞色素C 氧化酶，也是线粒体呼吸电子传递链主路和支路的共有成分，负责催化还原型细胞色素C 的氧化，并最终把电子传递给氧生成水。

还原型细胞色素C 在550nm 有特征光吸收，线粒体复合体Ⅳ催化还原型细胞色素C 生成氧化型细胞色素C ，因此550nm 光吸收下降速率能够反映线粒体复合体Ⅳ酶活性。

Reduced Cytochrome C （550nm ） Oxidized Cytochrome C注意：实验之前建议选择2-3个预期差异大的样本做预实验。

如果样本吸光值不在测量范围内建议稀释或者增加样本量进行检测。

需自备的仪器和用品：可见分光光度计/酶标仪、台式离心机、水浴锅/恒温培养箱、可调式移液器、微量玻璃比色皿/96孔板、研钵/匀浆器/细胞超声破碎仪、冰和蒸馏水。

操作步骤：一、样本处理（可适当调整待测样本量，具体比例可以参考文献）1. 称取约0.1g 组织或收集500万细胞，加入1.0 mL 提取液，用冰浴匀浆器或研钵匀浆。

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:EPZ015666 is an orally available inhibitor of PRMT5 enzymatic activity in biochemical assays with IC 50 of 22 nM and broad selectivity against a panel of other histone methyltransferases.IC50 & Target: IC50: 22 nM (PRMT5)[1]In Vitro: Treatment of MCL cell lines with EPZ015666 leads to inhibition of SmD3 methylation and cell death, with IC 50 values in the nanomolar range [1]. EPZ015666, a potent peptide–competitive and SAM–cooperative inhibitor with >10,000–fold specificity againstPRMT5 relative to other methyltransferases [2].In Vivo: EPZ015666 is orally bioavailable and amenable to in vivo studies. We performed 21–d efficacy studies in severe combined immunodeficiency (SCID) mice bearing subcutaneous Z–138 and Maver–1 xenografts, with twice–daily (BID) oral dosing on four dose groups: 25, 50, 100 and 200 mg per kilogram of body weight (mg/kg). After 21 d of continuous dosing, animals areeuthanized, and blood and tissues are analyzed to determine the relationship between methyl–mark pharmacodynamics andtumor–growth inhibition (TGI). EPZ015666 showed dose–dependent exposure and TGI after 21 d in both MCL models. Tumors in all EPZ015666 dose groups measured on day 21 showed statistically significant differences in weight, volume and tumor growth compared to vehicle–treated tumors. Dosing at 200 mg/kg BID induced tumor stasis in Z–138 cells, with >93% TGI after 21 d,whereas Maver–1 cells showed >70% TGI. Additionally, a third MCL xenograft is tested using the Granta–519 cell line, afast–growing model that reached endpoint on day 18 and showed dose–dependent efficacy with 45% TGI in the 200 mg/kg group.EPZ015666 is well tolerated in all three models, with minimal bodyweight loss in the 200 mg/kg dose group and no other clinical observations [1].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]EPZ015666 is serially diluted threefold from 1,000 to 0.051 nM and spotted into a 384–well polypropyleneV–bottom microplate. 3H–SAM is serially diluted twofold in assay buffer for a seven–point dilution series with a top concentration of 700 nM (final assay concentration). Reactions are initiated by the addition of 4 nM enzyme and 40 nM peptide (final assayconcentrations for both). Reactions are incubated for 60 min and quenched by the addition of 10 μL per well of 600 μM unlabeled SAM in assay buffer (final assay concentration). For the peptide competition, EPZ015666 is serially diluted threefold from 1,000 to 0.051 nM and spotted into a 384–well polypropylene V–bottom microplate. Peptide is serially diluted twofold in assay buffer for a seven–point dilution series with a top concentration of 480 nM (final assay concentration). Reactions are initiated by the addition of 4 nM enzyme and 75 nM 3H–SAM (final assay concentrations for both). Reactions are incubated for 60 min, and the reactions are quenched by the addition of 10 μL per well of 600 μM unlabeled SAM in assay buffer (final assay concentration)[1].Cell Assay: EPZ015666 is dissolved in DMSO and stored, and then diluted with appropriate medium (final DMSO 0.2%)before use [1].[1]Cultured cells in linear/log–phase growth are split to a seeding density of 2×105 cells/mL in 2–20 mL of media,depending on the yield required at the end of the growth period. Compound is diluted in DMSO and added to each culture vesselProduct Name:EPZ015666Cat. No.:HY-12727CAS No.:1616391-65-1Molecular Formula:C 20H 25N 5O 3Molecular Weight:383.44Target:Histone Methyltransferase Pathway:Epigenetics Solubility:DMSOwith a final DMSO concentration of 0.2%. Cells are allowed to grow for 96 h undisturbed. At the conclusion of each treatment period, cells are harvested by centrifugation (5 min, 1,200 rpm), and cell pellets are rinsed once with PBS before being frozen on dry ice pending further processing. Long–term proliferation assays are performed on all MCL lines, with slight adjustments to initial seeding densities, depending on growth characteristics for each cell line. All assays are carried out for 12 d[1].Animal Administration: EPZ015666 is formulated in 20% N–N–dimethylacetamide in water (Mice)[1].[1]Mice[1]Male CD–1 mice (25–40 g; n=6, with 3 per time point) are treated with a single dose of EPZ015666 at 2 mg/kg by intravenoustail–vein injection and 10 mg/kg by oral gavage administration, with both doses formulated in 20% N–N–dimethylacetamide in water. Animals are fasted overnight and weighed before dose administration on the day of dosing. Approximately 30 μL ofblood are taken from animals by submandibular or retro–orbital bleeding at pre–specified time intervals (seven time points). For the last time point (24 h), samples are collected via cardiac puncture while the animals are under anesthesia (70% CO2:30% O2). Blood samples are transferred into K2–EDTA tubes and placed on wet ice before centrifugation at 4°C (3,000g, 15 min) to obtain plasma within 30 min after sample collection. Plasma samples are stored at -70±10°C before protein precipitation and LC–MS/MS analysis. We constructed standard calibration curves by analyzing a series of control plasma aliquots containing 100 ng/mL labetalol as an internal standard and 1–3,000 ng/mL EPZ015666. Four levels of quality control are also included in the analysis (3–2,400 ng/mL EPZ015666). Data are analyzed using Phoenix WinNonlin 6.2.1.References:[1]. Chan–Penebre E, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015 Jun;11(6):432–7.[2]. Kryukov GV, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016 Mar 11;351(6278):1214–8.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

纤维素（CLL）含量检测试剂盒说明书微量法UPLC-MS-4117100T/96S试剂名称规格保存条件提取液一液体400mL×1瓶（自备）2-8℃保存提取液二液体100mL×1瓶2-8℃保存试剂一粉剂×2瓶2-8℃保存试剂二液体10mL×1瓶2-8℃保存标准品粉剂×1支2-8℃保存溶液的配制：1、提取液一：80%乙醇400mL，即将320mL无水乙醇和80mL蒸馏水混合，自备。

提供一个125mL空瓶。

2、标准品：10mg葡萄糖。

临用前加入1mL蒸馏水溶解，配成10mg/mL葡萄糖溶液备用，2-8℃保存两周。

3、工作液的配制：取一瓶试剂一中加入2.5mL试剂二，充分混匀，如较难溶解，可充分震荡或加热搅拌；用不完的试剂可以2-8℃保存一周。

纤维素是由β-D-葡萄糖单元以β-1,4-糖苷键连接而成的直链多聚体，通常与半纤维素、果胶及木质素结合在一起，是植物细胞壁的主要结构成分。

以纤维素为原料的产品广泛应用于食品、造纸、塑料、炸药、电工及科研器材等领域。

纤维素在酸性条件下加热能分解成β-D-葡萄糖。

在强酸作用条件下利用与蒽酮显色剂测定纤维素含量。

\Cellulose H2SO4β-D-Glucose H2SO45-Hydroxymethylfurfura5-Hydroxymethylfurfura+Anthrone Furfural Derivatives（620nm）最低检出限：0.0037mg/mL线性范围：0.00391-0.3mg/mL注意：实验之前建议选择2-3个预期差异大的样本做预实验。

如果样本吸光值不在测量范围内建议稀释或者增加样本量进行检测。

可见分光光度计/酶标仪、台式低温离心机、水浴锅、微量玻璃比色皿/96孔板、可调式移液枪、研钵/匀浆器、冰盒、丙酮、浓硫酸、无水乙醇、蒸馏水和EP管。

一、样本处理（可适当调整待测样本量，具体比例可以参考文献）1、细胞壁物质（CWM）的提取：（1）称取约0.3g（记为W1）样本，加入1mL提取液一，室温快速匀浆，90℃水浴20min，冷却至室温，6000g，25℃离心10min，弃上清。

Invitrogen的ICFC系列产品促销1．QPCR及QRT-PCR系列产品Invitrogen公司专门为中国客户提供的定量PCR试剂盒，结合了 UDG 防止残余污染技术和SYBR® Green I 荧光染料（存在于SYBR® Green I荧光定量PCR试剂盒中），在美国接受了严格的质量监控，可提供极高灵敏度的目的序列定量检测，线性剂量低，反应浓度范围很大。

qPCR Supermix-- 即用型反应剂，专为高特异性、实时定量DNA扩增设计UDG-- 防止携带污染物，减少克隆片段假阳性结果ROX参考染料-- 适用ABI仪器的校正染料产品信息活动时间：即日起至2009年4月30日2．Gibco南美胎牛血清即日起凡优惠价¥1780购买Gibco胎牛血清500ml（目录号:C2027050）即可获赠送价值¥250现金抵用券。

您可以凭现金抵用券在英韦创津公司购买任何商品，此券有效期至2009年5月31日。

产品信息活动时间：即日起至2009年4月30日独特的采集方式：GIBCO采用无菌心脏穿刺的方式采血原装直送，避免污染：原产地采集、加工、检测、包装。

完善的质控：采集、处理、检测、运输等环节都有文件和证书。

3．Invitrogen TA Cloning克隆产品专门用于克隆Taq聚合酶扩增的PCR产物。

采用pCR载体，能产生80%以上的重组产物，90%以上重组产物都包含插入片段。

产品信息活动时间：即日起至2009年5月31日附：pCR载体优点及图谱：3’-T突出端可直接连接Taq扩增的PCR产物可选择T7或T7和Sp6启动子进行体外RNA转录和测序侧向EcoRⅠ位点的通用多接头位点方便了插入片段的切离可以选择卡那霉素或氨苄青霉素进行筛选非常简便的蓝/白克隆筛选具有M13正向和反向引物位点，方便测序4．GIBCO液体培养基系列产品创立近50年的历史，品质优秀，产品种类丰富；为了中国用户利益，特建立国内生产线；所有产品，从原材料到生产全部按照GIBCO质量标准进行，每批均送抵美国公司总部质检合格后，才在国内销售。

•
•Thermo 反转录试剂盒K1622使用说明
•Thermo Scientific RevertAid First Strand cDNA Synthesis Kit是一套用于以RNA为模板高效合成第一链cDNA的完整系统，可合成长达13kb 的cDNA。

试剂盒配套提供的RiboLockRNase Inhibitor，可有效防止RNA模板的降解。

试剂盒配套提供oligo(dT)18引物和随机六聚体引物。

oligo(dT)18引物可以选择性地与mRNA中的poly (A)尾结合。

随机六聚体引物无需poly (A)尾，因此可转录mRNA 5’-端区域，也可以无poly
(A)尾的RNA (如micoRNA)为模板合成cDNA。

该试剂盒也可使用基因
特异性引物。

•Thermo 反转录试剂盒K1622使用说明优点：
•合成全长的第一链cDNA，最长可合成13kb的cDNA
•最佳反应温度为42℃
•完全一提供RT反应所需的所有组分
•应用:
•第一链cDNA合成，作为RT-PCR和实时RT-qPCR的模板
•构建全长cDNA文库
•反义RNA合成
•Thermo 反转录试剂盒K1622使用说明
•RevertAid First Strand cDNA Synthesis Kit合成全长cDNA
• 1 μg小鼠心脏总RNA作为模板，用oligo(dT)18 引物进行逆转录反应。

由此合成的cDNA，再作为Taq DNA Polymerase后续PCR扩增的模板。

末端2024 bp片段的成功扩增，表明长度为13.8 kb的全长RN***段得到成功的逆转录。

•。

专利名称：一种用于从血清中检测叶酸含量的解离剂及检测方法
专利类型：发明专利
发明人：陶然
申请号：CN201911416335.0
申请日：20191231
公开号：CN111024962A
公开日：
20200417
专利内容由知识产权出版社提供
摘要：本发明涉及一种用于从血清中检测叶酸含量的解离剂及检测方法，包括蛋白变性剂、蛋白水解酶、表面活性剂和基础液，其中各组分的用量为：每100ml解离剂中含有蛋白变性剂3～8g，蛋白水解酶1000～3000U，表面活性剂0.2～0.8ml，余量为基础液。

与现有技术相比，本发明具有方法简单，灵敏度高、检测结果准确等优点。

申请人：上海复星长征医学科学有限公司
地址：200444 上海市宝山区城银路830号
国籍：CN
代理机构：上海科盛知识产权代理有限公司
代理人：蒋亮珠
更多信息请下载全文后查看。

SMARTer™ PCR cDNA Synthesis Kit User Manual Cat. Nos. 634925 & 634926United States/Canada 800.662.2566Asia Pacific +1.650.919.7300Europe +33.(0)1.3904.6880Japan +81.(0)77.543.6116SMART er™ PCR cDNA Synthesis Kit User ManualT able of ContentsI. List of Components (3)II. Additional Materials Required (4)III. Introduction & Protocol Overview (5)IV. RNA Preparation & Handling (7)A. General Precautions (7)B. RNA Isolation (7)C. RNA Purity (8)D. Assessing the Quality of the RNA Template (8)V. SMART er cDNA Synthesis (9)A. General Considerations (10)B. PRoToCol: First-Strand cDNA Synthesis (10)C. PRoToCol: cDNA Amplification by lD PCR (12)VI. Analysis of cDNA Amplification Results (16)VII. T roubleshooting Guide (17)VIII. References (18)Appendix A: Protocols for PCR-Select™ (19)A. Additional Materials Required (19)B. PRoToCol: cDNA Amplification by lD PCR (19)C. PRoToCol: Column Chromatography (22)D. PRoToCol: RsaI Digestion (23)E. PRoToCol: Purification of Digested cDNA (23)F. Controls for PCR-Select cDNA Subtraction (25)G. Analysis of Results of SMARTer PCR cDNA Synthesis for PCR-Select cDNA Subtraction (25)H. T roubleshooting (27)Appendix B: Virtual Northern Blots (28)Appendix C: Protocol for Non-Directional Cloning of SMART er cDNA (29)A. Additional Materials Required (29)B. PRoToCol: ds cDNA Polishing (29)List of FiguresFigure 1. Flowchart of SMARTer cDNA synthesis (5)Figure 2. Guide to using the SMARTer cDNA synthesis protocol for PCR-Select cDNA Subtraction,Virtual Northerns, Non-Directional Cloning & library Construction, and other applications. (9)Figure 3. optimizing PCR parameters for SMARTer cDNA synthesis. (15)Figure 4. Analysis for optimizing PCR parameters (16)Figure 5. optimizing PCR parameters for SMARTer cDNA synthesis for use withClontech PCR-Select (21)Figure 6. Virtual Northern blot analysis of cDNA fragments expressed in cells producing γ-globin. (28)List of T ablesTable I: Guidelines for Setting Up PCR Reactions (12)Table II: Cycling Guidelines Based on Starting Material (13)Table III: T roubleshooting Guide for First-Strand cDNA Synthesis & SMARTer PCR Amplification (17)Table IV: T roubleshooting Guide for Preparing SMARTer cDNA for Subtraction (27)SMART er™ PCR cDNA Synthesis Kit User Manual I. List of ComponentsSMART er PCR cDNA Synthesis KitCat. No.Cat. No. 634925634926 10 rxns20 rxns Box 110 µl20 µl • SMART er II A Oligonucleotide (12 µM)5'–AAGCAGTGGTATCAACGCAGAGTACXXXXX–3' Rsa I(X = undisclosed base in the proprietary SMARTer oligo sequence) 5 µl5 µl • Control Mouse Liver T otal RNA (1 µg/µl)Box 210 µl20 µl • 3’ SMART CDS Primer II A (12 µM)5’–AAGCAGTGGTATCAACGCAGAGTACT (30)N -1N–3’Rsa I (N = A, C, G, or T ; N -1 = A, G, or C)200 µl 400 µl • 5’ PCR Primer II A (12 µM)40 µl 80 µl • 5X First-Strand Buffer (RNase-Free)250 mM T ris-HCl (pH 8.3)375 mM KCl30 mM MgCl 2100 µl 200 µl • dNTP Mix (dATP , dCTP , dGTP , and dTTP , each at 10 mM)50 µl 50 µl • Dithiothreitol (DTT ; 100 mM)10 µl 10 µl • RNase Inhibitor (40 U/µl)12 µl 25 µl • SMARTScribe™ Reverse T ranscriptase (100 U/µl)1 ml 1 ml • Deionized H 2O Box 310 20 • CHROMA SPIN™+TE-1000 ColumnsStorage ConditionsStore Control Mouse Liver T otal RNA and SMARTer II A Oligonucleotide at –70°C.• Store the CHROMA SPIN +TE-1000 Columns at room temperature.• Store all other reagents at –20°C.• Licensing InformationFor important information about the use of SMART technology, please see the Notice to Purchaser at theend of this user manual.要稀释本页已使用福昕阅读器进行编辑。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Sep.-13-2017Print Date:Sep.-13-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :CalcipotriolCatalog No. :HY-10001CAS No. :112965-21-61.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:MC 903; CalcipotrieneFormula:C27H40O3Molecular Weight:412.60CAS No. :112965-21-64. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature: 4°C, protect from light, stored under nitrogenShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

北京春达科技有限公司专营进⼝体外诊断试剂⼯业原料，透析产品，纯化填料，标准品SCLPP209碱性磷酸酶3.1.3.1Alkaline phosphatase from Calf intestine-Activity: >30000 U/mlGlycerol solution-Mw: 100,000-Store at -20 °CSCMAD211苹果酸脱氢酶1.1.1.37Malate dehydrogenase from Microorganism-Activity: >40 U/mgYellowish amorphous powder-Mw: 140,000-Store at -20 °CSCMDH18C苹果酸脱氢酶1.1.1.37Malate dehydrogenase from Pig heart-Activity: >1250 U/mgprot.White amorphous powder-Mw:140,000-Store at -20 °CSCMDL100苹果酸脱氢酶1.1.1.37Malate dehydrogenase from Microorganism-Activity: >60 U/mgWhite amorphous powder-Mw: 80,000-Store at -20 °CSCMUT11C变旋酶5.1.3.3Mutarotase from Porcine kidney-Activity: >1500 U/mgWhite amorphous powder-Mw: 40,000-Store at -20 °CSCMUT12C变旋酶5.1.3.3Mutarotase from Porcine kidney-Activity: >1000 U/mlAmmonium sulfate suspension-Mw: 40,000-Store at 2-8 °CSCNAL301唾液酸醛缩酶4.1.3.3N-Acetylneuraminic acid aldolase from MicroorganismActivity: >15 U/mg-Yellowish amorphous powderMw: 98,000-Store at -20 °CSCPCO301原⼉茶酸3,4双加氧酶1.13.11.3Protocatechuate 3,4-dioxygenase from Pseudomonas sp.Activity: >3 U/mg-Light brown amorphous powderMw: 700,000-Store at -20 °CSCPEO131过氧化物酶1.11.1.7Peroxidase from Horseradish, Grade IActivity: >250 U/mg-Reddish-brown amorphous powderMw: 40,000-Store at -20 °CSCPEO301过氧化物酶1.11.1.7Peroxidase from Horseradish, Grade I-Activity: >250 U/mgReddish-brown amorphous powder-Mw: 40,000-Store at -20°CSCPEO302过氧化物酶1.11.1.7Peroxidase from Horseradish, Grade III-Activity: >110 U/mgReddish-brown amorphous powder-Mw: 40,000-Store at -20°CSCPHO12C磷脂酶D Phospholipase D from Streptomyces chromofuscus3.1.4.4Activity: >40 U/mg-Brown amorphous powderMw: 57,000-Store at -20 °CSCPNP301嘌呤核苷磷酸化酶2.4.2.1Purine-nucleoside phosphorylase from MicroorganismActivity: >15 U/mg-White amorphous powderMw: 120,000-Store at -20 °CSCPPC301磷酸烯醇式丙酮酸羧化酶4.1.1.31Phosphoenolpyruvate carboxylase from Corn leavesActivity: >5 U/mg-White amorphous powderMw: 390,000-Store at -20 °CSCPSP101脯氨酸特定的肽链内切酶3.4.21.26Proline specific endopeptidase from Flavobacterium sp.Activity: >5 U/mg-White amorphous powder-Mw: 78,000-Store at -20 °CSCPYK302L丙酮酸激酶2.7.1.40Pyruvate kinase from Rabbit muscle-Activity:＞2000 U/mlwhite ammonium sulphate suspension-Mw:237000-Store at 2-8℃SCPYO311丙酮酸氧化酶1.2.3.3Pyruvate oxidase from Microorganism-Activity: >1.5 U/mgYellowish amorphous powder-Mw: 260,000-Store at -20 °CSCSAO341肌氨酸氧化酶1.5.3.1Sarcosine oxidase from Microorganism-Activity: >8 U/mgYellowish amorphous powder-Mw: 65,000-Store at -20 °CSCSAO351肌氨酸氧化酶1.5.3.1Sarcosine oxidase from Microorganism-Activity: >8 U/mgYellowish amorphous powder-Mw: 43,000-Store at -20 °CSCSOD302超氧化物歧化酶1.15.1.1Superoxide dismutase from Bovine erythrocyte-Activity: >3000U/mgBluish-green amorphous powder-Mw: 32,000-Store at -20 °CSCUAO201尿酸酶1.7.3.3Uricase from Candida sp.-Activity: >4 U/mg-White amorphous powder-Mw: 120,000-Store at -20 °CSCUAO211尿酸酶1.7.3.3Uricase from Bacillus sp.-Activity:>1.5 U/mg-White amorphous powder-Mw: 150,000-Store at -20 °CSCURH10S脲酶3.5.1.5Urease from Jack bean-Activity: >220 U/mg-White amorphous powder-Mw: 480,000-Store at -20 °CSCURH16C脲素酶GUrease G from Jack bean-Activity: >150 U/mgWhite amorphous powder-Mw: 480,000-Store at -20 °C3.5.1.5SCURH201脲素酶Urease from Jack bean-Activity: >100 U/mgWhite amorphous powder-Mw: 480,000-Store at -20 °C3.5.1.5SCXTO212黄嘌呤氧化酶Xanthine oxidase from Microorganism-Activity: >10 U/mgReddish-brown amorphous powder-Mw: 160,000-Store at -20°C1.1.3.222.诊断与研究⽤的辅酶CODES PRODUCTS CAS #SCADP01C 腺苷5'-⼆磷酸单钾盐⼆⽔合物ADP-K.2H2O-Adenosine 5’-diphosphate monopotasium saltdihydrate-C10H14N5O10P2K.2H2O-Mw:501.30-Colorless crystals-Purity:>95 %72696-48-1SCADP22C 腺苷5’-⼆磷酸⼆钠盐ADP-Na2-Adenosine 5’-diphosphate disodium salt-C10H13N5O10P2Na2-Mw:471.20-White powder-Purity:>98 %16178-48-6SCAMP02C 腺苷-5’-磷酸AMP-Adenosine 5’-monophosphoric acid-C10H14N5O7P.H2O-Mw:365.20-White powder-Purity:>98 %18422-05-4SCAMP05C 腺苷5’-磷酸AMP-Na2-Adenosine 5’-monophosphate disodium salt -C10H12N5O7PNa2-Mw:391.18-White powder-Purity:>95%18422-05-4SCATP03C 腺苷5’-三磷酸⼆钠盐3⽔合物ATP-Na2.3H2O-Adenosine 5’-triphosphate disodium salttrihydrate -C10H14N5Na2O13P3.3H2O -Mw:605.19-White powder-Purity:>96 %987-65-5SCBNA207C β-烟酰胺-腺嘌呤⼆核苷酸NAD-β-Nicotinamide-adenine dinucleotide-C21H27N7O14P2-Mw:663.4-White powder-Purity:>98 %53-84-9SCBND210C β-烟酰胺腺嘌呤⼆核苷磷酸，还原型四钠盐NADPH-Na4-β-Nicotinamide-adenine dinucleotide phosphate, reducedtetrasodium salt-C21H26N7O17P3.Na4-Mw:833.40-White powder-Purity:>93 %2646-71-1SCBNH208C β-烟酰胺腺嘌呤⼆核苷酸，还原⼆钠盐NADH-Na2-β-Nicotinamide-adenine dinucleotide, reduceddisodium salt -C21H27N7P2O14Na2-Mw:709.40-White to yellowish powder-Purity:>93 %606-68-8β-烟酰胺腺嘌呤⼆核苷酸磷酸⼆钠盐24292-60-2SCBNP209C β-烟酰胺腺嘌呤⼆核苷酸磷酸⼆钠盐NADP-Na2-β-Nicotinamide-adenine dinucleotide phosphatedisodium salt-C21H26N7O17P3Na2-Mw:787.40-Yellowishpowder-Purity:>97 %24292-60-2SCCOA11C 辅酶A三锂盐Coenzyme A trilithium salt-C21H33Li3N16O7P3S-Mw:785.40-White powder-Purity:>85 %18439-24-2SCDAD631C ⼆(腺苷-5’-)五磷酸三锂盐Ap5A-Li3-P1,P5 –Di(adenosine -5’-)pentaphosphate trilithiumsalt-C20H26N10O22P5Li3-Mw:934.20-Yellowish powder-Purity:>95 %75522-97-3SCFAD11C 黄素腺嘌呤⼆核苷酸⼆钠盐FAD- Na2-Flavine-adenine dinucleotide disodium salt-C27H31N9O15P2Na2-Mw:829.60-Orange powder-Purity:>93 %146-14-5SCNAL24C N-⼄酰-L-半胱氨酸N-Acetyl-L-cysteine-C5H9NO3S-Mw:163.20-White powder-Purity:>98 %616-91-1SASNAD 硫代辅酶IThio-NAD-C21H27N7O13SP2-Purity:≥ 90%4090-29-3SASNADP 硫代辅酶IIThio-NADP-C21H27N7O16P3S•Na- Purity:≥ 90%19254-05-8SAAldNAD 3-吡啶⼄醛腺嘌呤⼆核苷酸3-Pyridinealdehyde adenine dinucleotide C21H27N6O14P21986-7-7SAAC1023-⼄酰基吡啶腺嘌呤⼆核苷酸磷酸钠(Ac-NADP) APADP-C22H28N6O17P3•Na -Purity:≥ 80%102029-67-4SANAAD 烟酸腺嘌呤⼆核苷酸Nicotinic Acid Adenine Dinucleotide- C21H26N6O15P2104809-30-5SADeNAD 脱氨基NADDeamino Nicotinamide Adenine Dinucleotide-C21H26N6O15P2104809-38-3SAGGNAFB γ-L-⾕氨酰基-4-硝基苯胺Gamma-L-glutamyl-4-nitroanilide,-C11H13N3O5-Purity:≥ 96%7300-59-6SACGGN L-γ-⾕氨酸-(3-甲酸-4硝基苯胺)铵盐L-Glutamic Acid Gamma- (3-Carboxy-4-Nitroanilide),Ammonium Salt-C12H12N3O7P•NH4-Purity:≥ 96%63699-78-5SAPEPCHA 磷酸烯醇丙酮酸单环⼰胺盐PEP-C3H4O6P•C6H13N-Purity :＞95%10526-80-4SAPEPK 磷酸烯醇式丙酮酸单钾盐PEP-C3H4O6P•K-Purity :＞95%4265-07-03.诊断与研究⽤的底物CODES PRODUCTS CAS #SCAKE05C α–酮戊⼆酸⼆钠盐⼆⽔合物α–Ketoglutaric acid, disodium salt dihydrate-C5H4O5Na2.2H2O-Mw:226.10 -White powder-Purity:>98%305-72-6α–酮戊⼆游离酸328-50-7SCAKE115C α–酮戊⼆游离酸α–Ketoglutaric free acid-C5H4O5-Mw:146.10 -White powder-Purity:>99%328-50-7SCBTC06S-丁酰硫胆碱碘S-Butyrylthiocholine Iodide-C9H20NOSI-Mw:317.23 -White powder-Purity:>97%1866-16-6SCCNP005Gal-G2-α-CNP-C28H51O18Cl-Mw:659.98 -White powder-Purity:>90 %157381-11-8SCCRP59C 磷酸肌酸⼆钠盐四⽔合物Phosphocreatine disodium salt tetrahydrate-C4H8N3O5PNa2.4H2O-Mw:327.15 -White powder-Purity:>97 %19333-65-4SCGGC106C ⽢氨酰⽢氨酸Glycylglycine-C4H8N2O3-Mw:132.12-White powder-Purity:>98 %556-50-3SCGLT100L-⾕氨酸L-Glutamic acid-C5H9N2O4- Mw:147.13-White powder-purity:＞99%617-65-2SCGPS15C 葡萄糖-6-磷酸⼆钠盐Glucose-6-phosphate disodium salt-C6H11O9PNa2-Mw:304.20-White powder-Purity:>95 %3671-99-6SCLAC171C DL-乳酸锂盐DL-Lactic acid Lithium salt-C3H5O3Li-Mw:96.01-White powder-Purity:>95%16891-53-5SCLAL29C L-丙氨酸游离酸L-Alanine free acid-C3H7NO2-Mw:89.09-White powder-Purity:>99%56-41-7SCLAP41C L-天门冬氨酸L-Aspartic acid-C4H7NO4-Mw:133.10-White powder-Purity:>99 %56-84-8SCLAP42C L-天门冬氨酸,钠盐⼀⽔合物L-Aspartic acid, sodium salt monohydrate-C4H6NO4Na.H2O-Mw:173.10-White powder-Purity:>98 %323194-76-9SCLAP43C L-天门冬氨酸,镁⼆⽔合物L-Aspartic acid, magnesium salt dihydrate-C8H12N2O8Mg.2H2O-MW:324.50-White powder-Purity:>98 %2068-80-6SCLGC244C L-γ-⾕氨酰-3-羧基-4-硝基苯胺Glupa C-L-γ-Glutamyl-3-carboxy-4-nitranilide-C12H12N3O7NH4-Mw:328.30-Yellow powder-Purity:>99 %63699-78-5SCNAY138C 萘磷酸单钠盐Naphtyl phosphate, monosodium salt-C10H8NaO4P.H2O-Mw:264.15-White powder-Purity:>98%81012-89-7SCPG701C 亚⼄基降-4-硝基苯基-β-D-麦芽庚糖苷pNP-G7-Ethylidene-4-nitrophenyl-D-maltoheptaoside-C50H77NO38-Mw:1300.10-Yellowish powder-Purity:>90%96597-16-9对硝基苯基磷酸酯，⼆钠盐六⽔合物4264-83-9SCPNP264C 对硝基苯基磷酸酯，⼆钠盐六⽔合物PNPP-p-Nitrophenylphosphate, disodium salt hexahydrate-C6H4NO6PNa2.6H2O-Mw :371.10-White to yellow powder-Purity:>98%4264-83-9SCPNS265C p-硝基苯基磷酸酯，⼆tris盐PNPP diTris-p-Nitrophenylphosphate, ditris salt-C14H28N3O12P-Mw:461.40-White powder68189-42-4SCPYN100丙酮酸钠Sodium pyruvate-C3H3NaO3-Mw:110-White powder-Purity:>99%113-24-64.缓冲液Buffers for diagnostic & researchPRODUCTS CAS # N-(2-⼄酰胺基)-2-氨基⼄磺酸ACES-N-(2-Acetamido)-2-aminoethanesulfonic acid7365-82-4N-(2-⼄酰胺基)亚氨基⼆⼄酸ADA-(N-(2-Acetamido)iminodiacetic acid)26239-55-4 2-氨基-2-甲基-1-丙醇AMT -2-amino-2-methyl-1-propanol124-68-5 N,N-双(2-羟⼄基)-2-氨基⼄磺酸BES-N,N-Bis-(2-Hydroxyethyl)-2-Aminoethanesulfonic acid10191-18-1 N,N-双-(2-羟基⼄基)⽢氨酸Bicine-N,N-Bis-(2-Hydroxyethyl)glycine150-25-4 N-环⼰基-3-氨基丙磺酸CAPS-N-Cyclohexyl-3-aminopropanesulfonicacid1135-40-6N-环⼰基-2-羟基-3-氨基丙磺酸CAPSO -N-Cyclohexyl-2-hydroxy-3-aminopropanesulfonic acid73463-39-5。

WHO International Standard1st WHO International Standard for Human Papillomavirus (HPV)Type 16 DNA NIBSC code: 06/202 Instructions for use(Version 2.0, Dated 10/11/2010)1. INTENDED USEThe 1st International Standard for HPV Type 16 (HPV-16) DNA Nucleic Acid Amplification Techniques consists of a freeze-dried preparation of recombinant plasmid containing full-length HPV-16 DNA cloned via its unique BamH1 site (Quint et al., 2006). The standard has been formulated in a background of purified human genomic DNA, lyophilized in 0.5 ml aliquots and stored at -20 °C. The material was calibrated in an international collaborative study involving 19 laboratories (Wilkinson et al., 2008). The International Standard contains material that is proprietory to third parties and should be used for the sole purpose of calibrating in-house or working standards for the amplification and detection of HPV-16 DNA. The International Standard should not be used for any other purpose and should be discarded after use. 2. CAUTIONThis preparation is not for administration to humans .This material contains DNA derived from C33A cells. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.3. UNITAGEThe 1st International Standard for HPV-16 DNA Nucleic Acid Amplification Techniques has been assigned a unitage of 5 x 106 International Units (IU) per ampoule.Traceability statement:It was proposed at a WHO meeting in January 2008 (WHO Meeting Report, 2008) that the instructions for use of the International Standard for HPV-16 DNA include the calculations and assumptions used in determining the theoretical HPV-16 qenome equivalents (GEq) of the bulk material used in formulating the International Standard, thus demonstrating that 1 IU is equivalent to 1 GEq for HPV-16 DNA . The definitive unitage of the 1st WHO International Standard for HPV-16 DNA therefore remains as IU while the traceability statement would allow users to equate IU with GEq.Assays for DNA concentration of the recombinant HPV-16 plasmid stock preparation were performed in Dr Cosette Wheeler‟s laboratory, University of New Mexico (UNM). DNA concentrations were determined by absorbance at 260 nm as well as spectrofluorometrically using the Picogreen assay (Invitrogen Corporation, USA). A correlation coefficient of 0.95 or higher was obtained between the two DNA measurements. 10 ng HPV-16 plasmid DNA/μl was supplied to NIBSC for formulating the bulk material for subsequent freeze-drying. The UNM laboratory also provided NIBSC with a statement indicating that 1.0 x 1011 GEq/ml for HPV-16 is equal to 1.17 ng/μl. 10 ng HPV-16 plasmid DNA/μl plasmid stock preparation is therefore equivalent to 8.547 x 1011 HPV-16 GEq/ml. NIBSC used this data in formulating the 1st International Standard for HPV Type 16 DNA.Formulation of bulk material for the 1st International Standard for HPV Type 16 DNA (NIBSC code 06/202):At NIBSC, the bulk HPV-16 plasmid DNA material was prepared according to the formula:HPV GEq/ml of bulk material = (HPV GEq/ml of plasmid stock x volume plasmid stock) / volume bulk material.Therefore,HPV-16 GEq/ml of bulk material = (8.547 x 1011 HPV-16 GEq/ml plasmid stock) x (0.02223 ml HPV-16 plasmid stock) / 1900 ml HPV-16 bulk material = 1.0 x 107 HPV-16 GEq/ml bulk materialThe HPV-16 DNA bulk material was subsequently freeze-dried in 0.5 ml aliquots.Certain assumptions are required for equating IU to GEq for the 1st International Standard for HPV-16 DNA: 1) 1.0 x 1011 GEq/ml for HPV-16 is equal to 1.17 ng/μl. 2) There is no loss in activity of the HPV-16 DNA upon lyophilization. 3) The recombinant HPV-16 plasmid DNA accurately mimics the activity of HPV-16 viral DNA in biological samples.Independent calculation of GEq/ml for recombinant HPV-16 plasmid DNA.NIBSC also independently calculated the genome equivalence of the HPV-16 plasmid stock preparation and bulk preparation in which the molecular weights of the full-length HPV-16 genome and pBR322 DNA were based on sequence content using BioEdit Sequence Alignment Editor v7.0.5.3 (Tom Hall, Isis Pharmaceuticals Inc., USA). The sequences used for determining the molecular weights are GenBank Accession number J01749.1 for pBR322 and the reference sequence for HPV16 (Accession K02718).BioEdit dataDNA molecule: HPV16 Accession K02718 Length = 7904 base pairsMW= 4786756.00 Daltons, double strandedDNA molecule: cloning vector pBR322 Length = 4361 base pairsMW= 2653867.00 Daltons, double strandedFormulaeGEq/ml of the HPV plasmid stock was calculated according to the formula: GEq/ml of the HPV plasmid stock = (DNA concentration of HPV plasmid stock) x (MW of HPV DNA + MW of pBR322)-1 x (Avogadro‟s Number) where Avogadro‟s Number = 6.022x1023 molecules/molGEq/ml of the bulk HPV DNA materials was calculated according to the formula:HPV GEq/ml of bulk material = (HPV GEq/ml of plasmid stock x volume plasmid stock) / volume bulk material.CalculationThe recombinant HPV-16 plasmid stock preparation was supplied to NIBSC at a concentration of 10 ng/μl. Using the MW determinations shown above, the GEq/ml of the HPV-16 plasmid stock is:= (10 x 10-9 g/μl) x (mol/(7440623 g) x (6.022x1023 molecules/mol) = 8.093 x 108 molecules/μl = 8.093 x 1011molecules/ml = 8.093 x 1011 HPV-16 GEq/ml22.23μl of the recombinant HPV-16 plasmid stock was diluted to a final volume of 1900ml, therefore,HPV-16 GEq/ml of bulk material = (8.093 x 1011 HPV-16 GEq/ml plasmid stock) x (0.02223 ml HPV-16 plasmid stock) / 1900 ml HPV-16 bulk material = 0.947 x 107 HPV-16 GEq/ml bulk material4. CONTENTSCountry of origin of biological material: United Kingdom.Each ampoule contains the lyophilized equivalent of 0.5 ml HPV-16 plasmid DNA in 10mM Tris buffer pH7.4 containing 1mM EDTA, 5 mg/ml trehalose and ~1 x 106 human GEq/ml derived from C33a cells.5. STORAGEThe ampoule should be stored at -20 °C or below on receipt.Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.6. DIRECTIONS FOR OPENINGDIN ampoules have an …easy -open‟ coloured stress point, where the narrow ampoule stem joins the wider ampoule body.Tap the ampoule gently to collect the material at the bottom (labeled) end. Ensure that the disposable ampoule safety breaker provided is pushed down on the stem of the ampoule and against the shoulder of the ampoule body. Hold the body of the ampoule in one hand and the disposable ampoule breaker covering the ampoule stem between the thumb and first finger of the other hand. Apply a bending force to open the ampoule at the coloured stress point, primarily using the hand holding the plastic collar.Care should be taken to avoid cuts and projectile glass fragments that might enter the eyes, for example, by the use of suitable gloves and an eye shield. Take care that no material is lost from the ampoule and no glass falls into the ampoule. Within the ampoule is dry nitrogen gas at slightly less than atmospheric pressure. A new disposable ampoule breaker is provided with each DIN ampoule.7. USE OF MATERIALNo attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution.The 1st International Standard for HPV-16 DNA contains high copy number template. There is a high risk of HPV-16 plasmid DNA contamination via aerosolization upon opening of the glass ampoule. The material must be opened and handled in a separate laboratory environment, away from other pre-amplification components such as reagents, labware and samples.The material is supplied lyophilized and, before use, should be reconstituted in 0.5 ml sterile nuclease-free water. Ensure that the inside surface of the ampoule is wetted with the added water so that any particles of freeze-dried material adhering to the glass are reconstituted. The reconstituted material has a final concentration of 1 X 107 IU/ml. The reconstituted material is suitable for calibration of in-house or working standards for the amplification and detection of HPV-16 DNA.. The material is not suitable for calibrating or assessing extraction, precipitation or centrifugation procedures. The material has NOT been calibrated for human DNA nucleic acid amplification techniques.8. STABILITYReference materials are held at NIBSC within assured, temperature-controlled storage facilities. The 1st International Standard for HPV-16 DNA should be stored at -20 °C or below on receipt.Studies on the stability of reconstituted standard are underway. Users should determine the stability of the reconstituted material according to their own method of preparation, storage and use.NIBSC follows the policy of WHO with respect to its reference materials.9. REFERENCESQuint, W. G. V., Pagliusi, S. R., Lelie, N., de Villiers, E. M., Wheeler, C. M. and the World Health Organization Human Papillomavirus DNA International Collaborative Study Group. (2006). Results of the First WorldHealth Organization International Collaborative Study of Detection of Human Papillomavirus DNA. J. Clin. Microbiol. 44: 571-579.Wilkinson, D.E., Baylis, S.A., Padley, D., Heath, A.B., Ferguson, M., Pagliusi, S.R., et al. Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int J Cancer 2010 Jun 15;126(12):2969-83.WHO meeting report, on “Standardization of HPV assays and the role of HPV LabNet in supporting vaccine introduction” Geneva, Switzerland, 23-25 January 2008, in preparation.10. ACKNOWLEDGEMENTS11. FURTHER INFORMATIONFurther information can be obtained as follows; This material: enquiries@ WHO Biological Standards:http://www.who.int/biologicals/en/JCTLM Higher order reference materials: /en/committees/jc/jctlm/ Derivation of International Units:/products/biological_reference_materials/frequently _asked_questions/how_are_international_units.aspx Ordering standards from NIBSC:/products/ordering_information/frequently_asked_q uestions.aspxNIBSC Terms & Conditions:/terms_and_conditions.aspx12. CUSTOMER FEEDBACKCustomers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@13. CITATIONIn all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.15. LIABILITY AND LOSSInformation provided by the Institute is given after the exercise of all reasonable care and skill in its compilation, preparation and issue, but it is provided without liability to the Recipient in its application and use. It is the responsibility of the Recipient to determine the appropriateness of the standards or reference materials supplied by the Institute to the Recip ient (“the Goods”) for the proposed application and ensure that it has the necessary technical skills to determine that they are appropriate. Results obtained from the Goods are likely to be dependant on conditions of use by the Recipient and the variability of materials beyond the control of the Institute.All warranties are excluded to the fullest extent permitted by law, including without limitation that the Goods are free from infectious agents or that the supply of Goods will not infringe any rights of any third party.The Institute shall not be liable to the Recipient for any economic loss whether direct or indirect, which arise in connection with this agreement.The total liability of the Institute in connection with this agreement, whether for negligence or breach of contract or otherwise, shall in no event exceed 120% of any price paid or payable by the Recipient for the supply of the Goods.If any of the Goods supplied by the Institute should prove not to meet their specification when stored and used correctly (and provided that the Recipient has returned the Goods to the Institute together with written notification of such alleged defect within seven days of the time when the Recipient discovers or ought to have discovered the defect), the Institute shall either replace the Goods or, at its sole option, refund the handling charge provided that performance of either one of the above options shall constitute an entire discharge of the Institute‟s liability under this Condition.。

肉毒碱棕稠酰转移酶（CPT-I ）试剂盒说明书微・法IOO 管用6样注意:正式测定前务必取2・3个预期差异较大的样本做预测定渊定意义：肉毒碱棕桐酰转移醉是存在于线粒体内膜的一类酰基转移随。

可逆地催化从酰基辅函A 将酰基转移至1-肉毒碱的反应，在转运脂肪酸通过线粒体内膜的过程中起重要作用。

涌定原理：基于肉碱和脂酰辅酶A 在丙二酰辅酶A 存在与否的条件下，通过肉碱脂酰转移酶（CPT ”的作用，产生脂酰肉碱，并释放出琉基辅酶A （CoA-SH ）,与EHman 试剂DN-TB 反应后，产生黄色的TNB 。

通过其吸收峰值得变化（412nm ）,来定量分析CPT-I 的活性。

需自备的仪器和用品：可见分光光度计/酶标仪、台式离心机、水浴锅、可调式移液器、微量石英比色皿/96孔板、研钵、冰、无水乙醇和蒸储水试剂组成和配制：试剂一：液体IOOm1X1瓶，-20^C 保存：试剂二：液体20m1χ1瓶，-20℃保存；试剂三：液体1.5m1χ1支，-20℃保存；试剂四：液体30m1χ1瓶，49保存；试剂五：粉剂X1瓶，4"C 保存；试剂六：粉剂X1支，-2（ΓC 保存；样本的前处理：组织、细菌或细胞中胞浆蛋白与线粒体蛋白的分离：称取约0.1g 组织或收集500万细胞，加入Im1试剂一和IOu1试剂三，用冰浴匀浆器或研钵匀浆。

将匀浆液于600g,4"C 离心5min 。

弃沉淀，将上清液移至另一离心管中，I1OOOg,4℃离心Iomin 。

上清液即胞浆提取物，可用于测定从线粒体泄漏的CPT-I （此步可选做）。

在步骤④的沉淀中加入200U1试剂二和2u1试剂三，超声波破碎（冰浴，功率20%或200W,超声3秒，间隔10秒，重夏30次），用于线粒体CPT-I 测定。

浦定步骤：1、分光光度计或酹标仪预热30min 以上，调节波长至412nm,蒸储水调零。

2、样本测定（1）在试剂五中加入Im1无水乙醉，混匀，再加入22m1试剂四，混匀，37*C （哺乳动物）或25C （其它物种）孵育5min ；用不完的试剂分装后-20℃保存，禁止反复冻融；（2）在试剂六中加入Im1蒸谣水，混匀，37C （哺乳动物）或25C （其它物种）孵育5min ；用不完的试①②③④⑤剂分装后-20C保存，禁止反复冻融：(3)在微量石英比色皿或96孔板中加入10U1样本、220U1试剂五和IoH1试剂六，混匀，记录412nm处20秒时的初始吸光度A1和2分20秒时的吸光度A2,计算ΔA=A2-A1,CPT-1活性计算：a.使用微■石英比色皿潴定的计算公式如下：(1)按样本蛋白浓度计算：单位的定义：每mg组织蛋白每分钟催化产生1nmo1TNB定义为一个酶活力单位。

Total Cites Impact5-Year ImmediacyArticles (linked to journal informationFactor Impact Index1439CA-CANCER J CLIN0007-923513722153.45988.5527.0425 6399NEW ENGL J MED0028-479324560551.65850.80712.667360 7457REV MOD PHYS0034-68613572044.98251.882 6.47846 1675CHEM REV0009-266511259641.29845.79514.335176 6266NAT REV GENET1471-00562335841.06336.4 6.31470 5693LANCET0140-673616692239.0636.4279.556313 6278NATURE0028-0836********.59738.1599.243869 6269NAT REV MOL CELL BIO1471-00723134137.16244.026 5.98565 668ANNU REV IMMUNOL0732-05821596336.55643.7428.42928 6247NAT MATER1476-11224634835.74942.3768.411141 6240NAT GENET1061-40368118335.20934.52 5.511225 6260NAT REV CANCER1474-175X326283539.361 6.33369 277ADV PHYS0001-8732484934.29431.1670.8577 6267NAT REV IMMUNOL1474-173********.12935.851 4.83165 6263NAT REV DRUG DISCOV1474-177********.07833.2058.65143 6232NAT BIOTECHNOL1087-01563872832.43832.1827.08792 1565CELL0092-867417876231.95734.366 6.499415 6272NAT REV NEUROSCI1471-003X2693831.67335.888 5.06562 6250NAT NANOTECHNOL1748-33872192031.1736.011 5.876121 7624SCIENCE0036-807550848931.02733.587 6.691832 6948PHYSIOL REV0031-93332253730.17438.707 2.53839 5608JAMA-J AM MED ASSOC0098-748412150429.97829.2738.504232 652ANNU REV BIOCHEM0066-41541942027.68131.964 4.31232 6252NAT PHOTONICS1749-48851399327.25431.5677.492120 7140PROG POLYM SCI0079-67001445726.38331.706 4.60756 3430IEEE ENG MED BIOL0739-5175291326.3038.0190 6245NAT IMMUNOL1529-29083246526.19925.005 4.961128 677ANNU REV PATHOL-MECH1553-4006232225.79419.915 6.38918 1599CELL STEM CELL1934-59091259325.31527.361 4.336122 5696LANCET ONCOL1470-20451700525.11721.856 6.536153 1678CHEM SOC REV0306-00124764624.89230.1817.997390 1500CANCER CELL1535-61082220024.75527.059 4.465114 5695LANCET NEUROL1474-44221516023.91722.959 4.47289 682ANNU REV PLANT BIOL1543-50081343823.65429.248 3.18527 6249NAT METHODS1548-70911924123.56523.231 4.404151 651ANNU REV ASTRON ASTR0066-4146824023.33334.261 2.21414 7125PROG MATER SCI0079-6425592123.19422.3337.21723 6912PHYS REP0370-157********.92922.99 6.69843 6248NAT MED1078-89565735022.86426.441 5.763186 6268NAT REV MICROBIOL1740-152********.4923.227 4.02969 6854PHARMACOL REV0031-69971033122.34522.114 2.33336 5764LIVING REV RELATIV1433-8351141722.33316.417 2.81811 6234NAT CHEM1755-4330865221.75723.02 5.532126 678ANNU REV PHARMACOL0362-1642720521.54321.6447.26926 15ACCOUNTS CHEM RES0001-48424211220.83324.633 5.295207 6233NAT CELL BIOL1465-73923222120.76120.691 3.97132 674ANNU REV NEUROSCI0147-006X1263820.61431.028 3.11526 5694LANCET INFECT DIS1473-30991047119.96618.095780 3581IMMUNITY1074-76133254619.79520.722 3.713164 680ANNU REV PHYSIOL0066-4278791419.54718.952 4.90521 6253NAT PHYS1745-24731800419.35219.367 6.854137 1098BEHAV BRAIN SCI0140-525X640218.57123.173 2.286144480J CLIN ONCOL0732-183X12867918.03817.255 4.836597 655ANNU REV CELL DEV BI1081-0706886617.98319.8060.78628 2458ECOL LETT1461-023X1753317.94918.495 1.403154 6221NANO TODAY1748-0132294417.68918.1920.78437 666ANNU REV GENET0066-4197677217.43621.7890.31232 1843CLIN MICROBIOL REV0893-85121205517.31319.065 2.21428 1422BRIT MED J1756-183********.21515.887.756328 6045MICROBIOL MOL BIOL R1092-2172907916.41717.718 1.51729 931ASTROPHYS J SUPPL S0067-00492476416.23814.437 3.074162 671ANNU REV MATER RES1531-7331525916.17914.4950.66718 8125TRENDS COGN SCI1364-66131571716.00816.845 4.05654 6356NEURON0896-62736952615.76616.403 2.603348 7191PSYCHOL BULL0033-29093081415.57519.676 2.31638 6271NAT REV NEUROL1759-4758229515.51813.994 1.65452 8126TRENDS ECOL EVOL0169-53472427915.38917.112 2.97476 7907SURF SCI REP0167-5729411515.33322.2817.758 6126MOL CELL1097-27654781815.2814.902 2.818296 683ANNU REV PSYCHOL0066-43081063515.26526.624 4.81822 7023PLOS MED1549-16761482015.25316.426 3.235115 6251NAT NEUROSCI1097-62564251915.25116.412 2.882228 1770CIRCULATION0009-732215228115.20215.385 2.98592 658ANNU REV CONDEN MA P1947-545462415.13915.139 5.13315 7122PROG ENERG COMBUST0360-1285476715.08917.778330 6262NAT REV CLIN ONCOL1759-4774276815.03114.931 2.660 6168MOL PSYCHIATR1359-41841268614.89713.985 3.879116 2532ENDOCR REV0163-769X1316614.87322.16 3.526 262ADV MATER0935-96489195214.82913.86 2.557867 458AM J PSYCHIAT0002-953X4273014.72114.396 2.574108 1583CELL METAB1550-41311243214.61917.551 3.25148 672ANNU REV MED0066-4219504314.60311.681 4.48635 389ALZHEIMERS DEMENT1552-5260290714.4838.672 2.2162 6236NAT CLIM CHANGE1758-678X84414.47214.5 2.65120 3122GENOME RES1088-90512885614.39714.104 3.416238 670ANNU REV MAR SCI1941-1405111414.36818.196 4.47621 5617JNCI-J NATL CANCER I0027-88743742414.33614.794 3.677124 95ACTA CRYSTALLOGR D0907-44491245314.1037.540.604182 2674EUR HEART J0195-668X3262914.09711.991 3.451273 4214J AM COLL CARDIOL0735-10977302114.08613.71 3.34427 597ANN INTERN MED0003-48194690513.97616.26 4.011176 7425REV GEOPHYS8755-1209646113.90613.333 2.0825 5849MAT SCI ENG R0927-796X485013.90218.9740.6676 5765LIVING REV SOL PHYS1614-496149813.833 1.8336 815ARCH GEN PSYCHIAT0003-990X3741213.77214.466 2.488125 529ANGEW CHEM INT EDIT1433-785122989413.73413.56 2.9592227 662ANNU REV ENTOMOL0066-4170877713.58914.047 3.09122 8134TRENDS NEUROSCI0166-22361788913.58214.466 2.31573 679ANNU REV PHYS CHEM0066-426X700213.36518.121 4.13829 7330REP PROG PHYS0034-48851022313.23214.937 3.55267 2892FEMS MICROBIOL REV0168-6445792613.23112.987 3.48152 4682J EXP MED0022-10076508813.21414.102 2.616190 8121TRENDS BIOCHEM SCI0968-00041564213.07612.005 2.40664 6219NANO LETT1530-69848843113.02514.132 2.4711078 6235NAT CHEM BIOL1552-44501081912.94815.6 3.715130 673ANNU REV MICROBIOL0066-4227844912.915.214 1.0825241ADV DRUG DELIVER REV0169-409X2156312.88815.431 1.488162 2296DEV CELL1534-58072030612.86114.091 2.174201 3076GASTROENTEROLOGY0016-50856040812.82112.835 3.424276 4471J CLIN INVEST0021-97389426412.81214.689 2.586394 7020PLOS BIOL1545-78852290812.6913.447 2.151152 654ANNU REV BIOPHYS1936-122X152912.6316.591 2.34626 1580CELL HOST MICROBE1931-3128610812.60913.567 2.943122 664ANNU REV FLUID MECH0066-4189675012.612.933 3.91323 3092GENE DEV0890-93695762712.44412.741 2.149249 657ANNU REV CLIN PSYCHO1548-5943204312.42214.073 1.44418 6241NAT GEOSCI1752-0894745112.36712.905 2.446148 7943SYST BIOL1063-51571141112.16913.316 2.80873 3590IMMUNOL REV0105-28961263412.15511.892 3.028106 55ACS NANO1936-0851*******.06212.524 1.941191 4200J ALLERGY CLIN IMMUN0091-67493607412.04710.108 2.752327 1010AUTOPHAGY1554-8627666112.0428.503 1.982114 3296HEPATOLOGY0270-91395012712.00311.4 2.169419 6275NAT STRUCT MOL BIOL1545-99932429911.90212.307 2.576184 7236Q REV BIOPHYS0033-5835227711.87512.163 1.2512 1761CIRC RES0009-73304644811.86111.028 2.465275 8137TRENDS PLANT SCI1360-138********.80811.675 2.1182 8124TRENDS CELL BIOL0962-89241103911.72112.095 2.32474 2544ENERG ENVIRON SCI1754-56921284911.65312.462 3.087473 2174CURR OPIN CELL BIOL0955-06741386611.4112.034 1.291110 6171MOL SYST BIOL1744-4292633511.3412.392 1.87757 215ADV APPL MECH0065-215696011.3337.1430.65 422AM J HUM GENET0002-92973468711.20212.512 2.188223 608ANN NEUROL0364-51343225611.19311.047 1.994173 462AM J RESP CRIT CARE1073-449X4971211.04110.919 2.705264 6264NAT REV ENDOCRINOL1759-5029202111.02511.479 1.85964 2070COORDIN CHEM REV0010-85452560111.01612.257 2.294136 653ANNU REV BIOMED ENG1523-9829315010.94614.5660.47419 4418J CELL BIOL0021-95257297410.82210.367 1.657283 7622SCI TRANSL MED1946-6234557410.75710.481 3.694219 3233GUT0017-57493071910.7329.988 3.821190 4213J AM CHEM SOC0002-786343128610.67710.237 2.1643099 1597CELL RES1001-0602702610.52610.216 2.84899 2789EUR UROL0302-28381708810.4768.083 4.043211 6265NAT REV GASTRO HEPAT1759-5045155210.4269.715 1.13666 6261NAT REV CARDIOL1759-5002167210.410.155 1.64751 661ANNU REV ECOL EVOL S1543-592X1490910.37516.8310.04821 6112MOL ASPECTS MED0098-2997301610.37510.821 1.46239 6115MOL BIOL EVOL0737-40383216810.35311.221 1.561294 3119GENOME BIOL1474-75961747810.2888.959 1.468154 1194BIOL REV1464-7931632610.25610.949 1.81153 7124PROG LIPID RES0163-7827389310.2510.69 1.58324 681ANNU REV PHYTOPATHOL0066-4286567610.22912.3130.69623 6255NAT PROD REP0265-0568660910.17810.072 2.38565 5735LEUKEMIA0887-69241825910.1648.692 2.401242 1505CANCER DISCOV2159-827463910.14310.143 2.97271 244ADV ENERGY MATER1614-6832199510.04310.05 2.118169 6237NAT COMMUN2041-1723732210.01510.02 2.096612 1360BRAIN0006-8950411899.91510.87 2.261280 4812J HEPATOL0168-8278222819.8588.897 2.863362516EMBO J0261-4189759509.8229.602 2.553333 7197PSYCHOL REV0033-295X213749.79711.342 1.22236 7141PROG QUANT ELECTRON0079-67277459.7868.29011 8129TRENDS GENET0168-9525107989.7729.325 2.10169 249ADV FUNCT MATER1616-301X347589.76510.342 1.815569 6273NAT REV RHEUMATOL1759-479019219.7459.318 1.44665 6692P NATL ACAD SCI USA0027-84245349519.73710.583 1.8933801 141ACTA NEUROPATHOL0001-6322116649.7348.562 2.565124 8122TRENDS BIOTECHNOL0167-779998339.669.289 1.61673 2132CSH PERSPECT BIOL1943-026439219.6310.3670.884155 1255BIOTECHNOL ADV0734-975066999.59911.85 1.248133 5984MED RES REV0198-632532979.5839.978 1.81137 8133TRENDS MOL MED1471-491459459.57110.142 1.48776 667ANNU REV GENOM HUM G1527-820423279.514.1250.620 921ASTRON ASTROPHYS REV0935-********.513.1947 2145CURR BIOL0960-9822431919.49410.445 2.307371 8131TRENDS IMMUNOL1471-490678509.4869.715 2.05178 2175CURR OPIN CHEM BIOL1367-593188699.4719.2560.98776 6377NEUROSCI BIOBEHAV R0149-7634129689.449.924 2.129147 7143PROG RETIN EYE RES1350-946235449.43910.188 1.57633 1828CLIN INFECT DIS1058-4838455569.3748.98 2.231523 2625EPIDEMIOL REV0193-936X29139.26919.051 3.07114 2571ENTERP INF SYST-UK1751-75755799.256 4.771 2.68222 6977PLANT CELL1040-4651390679.25110.125 1.526325 8136TRENDS PHARMACOL SCI0165-6147104179.2510.158 2.2774 1189BIOL PSYCHIAT0006-3223378409.2479.773 2.131251 6750PART FIBRE TOXICOL1743-897714719.1780.45544 676ANNU REV NUTR0199-988544909.15810.1880.920 2403DRUG RESIST UPDATE1368-764619659.1149.8130.8723 627ANN RHEUM DIS0003-4967270209.1118.351 2.308325 1278BLOOD0006-49711436709.069.338 2.1061251 6457NPG ASIA MATER1884-40493019.0428.556 2.41429 7129PROG NEUROBIOL0301-0082107149.03510.322 1.3275 1095BBA-REV CANCER0304-419X33349.03310.118 1.7560 4237J AM SOC NEPHROL1046-6673301328.9878.477 2.051195 8348WORLD PSYCHIATRY1723-861711938.974 6.413 2.42921 4133ISME J1751-736261298.9518.927 2.264208 8127TRENDS ENDOCRIN MET1043-276056138.9018.248 1.40574 3380HUM REPROD UPDATE1355-478656858.8479.512 1.88443 660ANNU REV EARTH PL SC0084-659746538.8339.861 1.51927 2246CYTOKINE GROWTH F R1359-610145878.8317.9190.58834 2186CURR OPIN IMMUNOL0952-791586898.7718.826 1.45284 2207CURR OPIN STRUC BIOL0959-440X101168.7389.02 1.45293 7728SLEEP MED REV1087-079229768.6818.26 1.94335 6371NEUROPSYCHOPHARMACOL0893-133X198828.6787.796 1.802248 1520CANCER RES0008-54721435228.658.576 1.539625 650ANNU REV ANAL CHEM1936-132711498.612.2830.69623 7022PLOS GENET1553-7404222128.5179.44 1.204691 7590SCHIZOPHRENIA BULL0586-7614116068.4868.934 1.699136 8058TOP CURR CHEM0340-102255078.456 6.205 4.27355 2202CURR OPIN PLANT BIOL1369-526694618.4559.221 1.22996 8132TRENDS MICROBIOL0966-842X82268.4348.09 2.15372 8038THORAX0040-6376177868.3767.808 2.371159 1577CELL DEATH DIFFER1350-9047145518.3718.395 2.2791901676CHEM SCI2041-652048458.3148.33 2.771458 6474NUCLEIC ACIDS RES0305-10481187158.2788.055 2.2051425 7656SEMIN LIVER DIS0272-808735158.274 6.8240.64937 6352NEUROLOGY0028-3878744088.2498.397 1.816527 1663CHEM MATER0897-4756746518.2387.627 1.123576 2190CURR OPIN MICROBIOL1369-527476958.238.104 1.06199 4330J AUTOIMMUN0896-841141688.145 6.075 1.30698 7026PLOS PATHOG1553-7374197438.1368.917 1.306627 2460ECOL MONOGR0012-961584478.0858.1290.84626 5271J PHOTOCH PHOTOBIO C1389-556720268.06911.9520.7516 3031FRONT NEUROENDOCRIN0091-302228427.98510.876 1.79329 5714LASER PHOTONICS REV1863-888015497.9768.779 2.44243 1000AUTOIMMUN REV1568-997250027.975 6.069 1.656163 6257NAT PROTOC1754-2189169227.9611.743 1.362174 6270NAT REV NEPHROL1759-506113547.9437.409 1.20663 6918PHYS REV LETT0031-90073621857.9437.435 2.176**** ****KIDNEY INT0085-2538380947.916 6.968 2.603234 2311DIABETES0012-1797461587.8958.611 1.542347 2172CURR OPIN BIOTECH0958-166995017.869.006 1.328131 6230NANOTOXICOLOGY1743-539013877.8447.758 1.24374 1374BRAIN STRUCT FUNCT1863-265312597.837 6.821 1.38255 1794CLIN CANCER RES1078-0432657047.8377.827 1.814665 7730SMALL1613-6810181377.8238.084 1.429457 1372BRAIN RES REV0165-017389037.8188.7860 8028THERANOSTICS1838-76404287.8067.806 1.98993 2517EMBO MOL MED1757-467612907.7959.39 1.698106 7054POLYM REV1558-372411557.79410.021 1.45511 6855PHARMACOL THERAPEUT0163-7258106557.7938.736 1.343108 1516CANCER METAST REV0167-765950167.78710.0880.85368 2312DIABETES CARE0149-5992490257.7357.555 2.234427 5846MASS SPECTROM REV0277-703739447.7359.924228 5716LASER PHYS LETT1612-201141167.714 4.9740.703158 7138PROG PHOTOVOLTAICS1062-799545357.7127.023 3.223112 7845STEM CELLS1066-5099182537.7018.368 1.297269 3374HUM MOL GENET0964-6906360417.6927.541 1.554478 7614SCI SIGNAL1937-914551687.6487.603 1.478182 4543J CONTROL RELEASE0168-3659297557.6338.078 1.136501 3024FRONT ECOL ENVIRON1540-929543167.61510.061 1.2560 7446REV MED VIROL1052-927617587.6157.024 1.35728 1204BIOMATERIALS0142-9612697927.6048.496 1.597898 5231J PATHOL0022-3417144687.585 6.928 2.376173 415AM J GASTROENTEROL0002-9270275217.5537.019 2.074188 4970J MAMMARY GLAND BIOL1083-302121207.524 5.838 1.225 656ANNU REV CHEM BIOMOL1947-54383317.5127.512 1.04522 7235Q REV BIOL0033-577033127.57.9040.1119 4037INT MATER REV0950-660822557.487.149 1.18816 876ARTHRITIS RHEUM-US0004-3591452007.4777.63 1.659411 1698CHEMSUSCHEM1864-563150567.4757.951 1.189286 2183CURR OPIN GENET DEV0959-437X81787.478.209 1.53880 7647SEMIN CANCER BIOL1044-579X42997.4367.107 2.22653 6140MOL ECOL RESOUR1755-098X47367.432 4.150.848132 7145PROG SOLID STATE CH0079-678614747.429 3.33806 675ANNU REV NUCL PART S0163-899821167.48.7770.73719 3210GONDWANA RES1342-937X43947.396 6.171 2.1341576220NANO RES1998-012430317.3927.8010.97996 615ANN ONCOL0923-7534228057.384 6.473 1.214541 6552ONCOGENE0950-9232605267.3577.18 2.218458 2436EARTH-SCI REV0012-825262047.3398.759 1.04981 2193CURR OPIN NEUROBIOL0959-4388114297.3358.165 1.111135 5064J MOL CELL BIOL1674-27886517.3088.271 1.75737 5298J PINEAL RES0742-309849567.304 5.451 1.10992 2593ENVIRON HEALTH PERSP0091-6765301117.267.522 1.56268 258ADV IMMUNOL0065-277623257.2568.020.87131 6132MOL CELL PROTEOMICS1535-9476142017.2518.051 1.532310 7206PSYCHOTHER PSYCHOSOM0033-319027617.23 5.825 1.26926 3201GLOBAL ECOL BIOGEOGR1466-822X52767.2237.284 1.935108 695ANTIOXID REDOX SIGN1523-0864118627.1897.548 1.991222 2518EMBO REP1469-221X105747.1897.396 1.68799 1796CLIN CHEM0009-9147265827.1497.192 2.737152 7146PROG SURF SCI0079-681619047.1369.140.27311 223ADV CARBOHYD CHEM BI0065-23188337.133 5.8460.754 2812EXERC IMMUNOL REV1077-55524387.053 5.2560.1258 6172MOL THER1525-0016127597.041 6.457 1.676219 6190MUCOSAL IMMUNOL1933-021*******.119 1.65767 3826INT J EPIDEMIOL0300-577114451 6.9827.001 3.281128 4205J AM ACAD CHILD PSY0890-856716470 6.977.148 2.0196 6223NANOMED-NANOTECHNOL1549-96343097 6.937.647 1.263160 2228CURR TOP DEV BIOL0070-21532246 6.912 6.4670.76242 6685P IEEE0018-921918840 6.9117.6940.697195 3200GLOBAL CHANGE BIOL1354-101318398 6.917.819 1.3297 6534OCEANOGR MAR BIOL0078-32182142 6.9099.8790.56 5139J NEUROSCI0270-6474160915 6.9087.8690.9781668 3362HUM BRAIN MAPP1065-947113379 6.8787.032 1.451226 3398HYPERTENSION0194-911X32323 6.873 6.984 1.588342 6518OBES REV1467-78815154 6.877.021 1.436101 6008METAB ENG1096-71762855 6.859 6.696 1.34772 1864CLIN PHARMACOL THER0009-923614263 6.846 6.349 1.995200 1627CEREB CORTEX1047-321121409 6.8287.463 2.05258 3224GREEN CHEM1463-926215554 6.828 6.992 1.269449 6929PHYS TODAY0031-92283738 6.762 5.263 1.51437 275ADV ORGANOMET CHEM0065-3055841 6.758.94103 6949PHYSIOLOGY1548-92132500 6.758.388 1.13829 6407NEW PHYTOL0028-646X26842 6.736 6.888 1.373378 929ASTROPHYS J0004-637X191940 6.733 5.945 2.0473075 1764CIRC-CARDIOVASC GENE1942-325X1641 6.728 6.398 1.17182 6921PHYS REV X2160-3308414 6.711 6.737 2.22571 6158MOL ONCOL1574-78911193 6.701 6.3790.91760 1768CIRC-HEART FAIL1941-32892007 6.684 6.67 1.41993 1309BMC MED1741-70152691 6.679 6.413 1.275109 1820CLIN GASTROENTEROL H1542-35658295 6.648 6.108 1.458179 6561ONCOTARGET1949-25531450 6.636 6.636 1.316114 2177CURR OPIN COLLOID IN1359-02944670 6.6297.0360.88443 2862EXPERT REV MOL MED1462-39941734 6.6230.78919 1417BRIT J PSYCHIAT0007-125021472 6.6067.112 1.872117 1019B AM METEOROL SOC0003-000711821 6.5917.704 2.48778 5280J PHYS CHEM LETT1948-71858575 6.585 6.651 1.301632 6902PHYS LIFE REV1571-0645659 6.583 6.699.45511 6990PLANT J0960-741232497 6.5827.113 1.5333456997PLANT PHYSIOL0032-088962407 6.5557.084 1.313469 5605JACC-CARDIOVASC INTE1936-87983378 6.552 6.834 1.603126 2396DRUG DISCOV TODAY1359-64468855 6.551 6.89 1.177158 271ADV MICROB PHYSIOL0065-29111006 6.545 6.267 1.25 1766CIRC-CARDIOVASC INTE1941-76401534 6.543 6.239 1.23797 1292BMC BIOL1741-70072631 6.531 6.384 1.69559 405AM J CLIN NUTR0002-916548233 6.5047.196 1.2325 2325DIABETOLOGIA0012-186X24906 6.487 6.772 1.749339 6150MOL INTERV1534-03841243 6.4818.0310 1490CAN MED ASSOC J0820-394611869 6.4657.53 1.766124 4906J INTERN MED0954-******** 6.455 5.913 1.609110 4465J CLIN ENDOCR METAB0021-972X68170 6.43 6.568 1.087809 6203MUTAT RES-REV MUTAT1383-57422736 6.4268.202122 6368NEUROPSYCHOL REV1040-73081611 6.427.5260.86229 353AIDS0269-937023034 6.407 6.131 1.679265 8059TOP ORGANOMETAL CHEM1436-60021152 6.384 1.76221 1643CHEM COMMUN1359-7345122728 6.378 6.226 1.533173 1557CATAL REV0161-49402529 6.37510.1750.8899 2780EUR RESPIR J0903-193625962 6.355 6.32 1.82317 222ADV CANCER RES0065-230X1890 6.351 5.5120.57121 8074TRAC-TREND ANAL CHEM0165-99367327 6.351 6.7610.92138 930ASTROPHYS J LETT2041-820545993 6.345 1.687670 7279RADIOLOGY0033-841945413 6.339 6.7380.832381 873ARTERIOSCL THROM VAS1079-564231851 6.338 6.986 1.097370 636ANN SURG0003-493236761 6.3298.264 1.15301 6973PLANT BIOTECHNOL J1467-76443136 6.279 5.813 1.04101 6139MOL ECOL0962-108330411 6.275 6.792 1.369445 2110CRIT REV TOXICOL1040-84442955 6.253 5.9720.94335 6339NEUROIMAGE1053-811961770 6.2527.063 1.2911222 2595ENVIRON INT0160-41209059 6.248 6.1220.935199 5339J PSYCHIATR NEUROSCI1180-48822253 6.242 6.473 1.64734 6226NANOSCALE2040-33647835 6.233 6.262 1.1671015 7886STUD MYCOL0166-06161237 6.231 6.813 4.1676 6869PHILOS T R SOC B0962-843626581 6.237.298 3.522289 2310DEVELOPMENT0950-199151191 6.208 6.888 1.258434 7648SEMIN CELL DEV BIOL1084-95215613 6.202 6.51 1.034116 3764INT J CANCER0020-713644529 6.198 5.474 1.39738 4915J INVEST DERMATOL0022-202X23976 6.193 6.065 1.898264 471AM J TRANSPLANT1600-613516088 6.192 6.014 1.506348 6318NEURO-ONCOLOGY1522-85173845 6.18 5.9470.694157 231ADV COLLOID INTERFAC0001-86867115 6.1698.01 1.3250 6320NEUROBIOL AGING0197-458015479 6.166 6.098 1.583537 5604JACC-CARDIOVASC IMAG1936-878X2977 6.164 6.703 1.717113 2080CORTEX0010-94525265 6.161 5.042 2.745106 7864STROKE0039-249952524 6.158 6.831 1.086567 1640CHEM BIOL1074-55219695 6.157 6.097 1.486144 6621ORG LETT1523-706073440 6.142 5.563 1.5721608 4378J BONE MINER RES0884-043122111 6.128 6.227 1.101257 6165MOL PLANT1674-20522346 6.126 5.77 1.585118 2094CRIT CARE MED0090-349332733 6.124 6.401 2.614363 2371DIVERS DISTRIB1366-95164336 6.122 5.7430.935107 1863CLIN PHARMACOKINET0312-******** 6.109 5.4860.98154 8313WHO TECH REP SER0512-******** 6.1 3.2560.35714 8039THROMB HAEMOSTASIS0340-624517392 6.094 4.782 1.3462465510J THROMB HAEMOST1538-793314645 6.081 6.176 1.17265 5876MATER TODAY1369-70213769 6.0718.677 1.97744 1578CELL DEATH DIS2041-48891481 6.044 6.0440.565191 4548J COSMOL ASTROPART P1475-751613656 6.036 5.295 2.387555 1523CANCER TREAT REV0305-73724233 6.024 6.246 1.458107 7131PROG NUCL MAG RES SP0079-65651993 6.022 6.065 1.38918 1285BLOOD REV0268-960X17706 6.6620.76939 7877STRUCTURE0969-212612441 5.994 6.081 1.466191 2519EMERG INFECT DIS1080-604021567 5.993 6.312 1.689244 322AGEING RES REV1568-16371965 5.953 6.549 1.43941 7706SIAM REV0036-14455051 5.9528.4140.40922 1763CIRC-ARRHYTHMIA ELEC1941-31492173 5.947 6.434 1.175143 2108CRIT REV SOLID STATE1040-8436744 5.9477.368110 1543CARDIOVASC RES0008-636320689 5.94 6.113 1.689222 3241HAEMATOL-HEMATOL J0390-607811392 5.935 6.002 1.454251 7654SEMIN IMMUNOL1044-53233190 5.9267.250.89146 6031METHODS ECOL EVOL2041-210X822 5.92460.854123 203ADDICT BIOL1355-62151977 5.914 5.322 1.01193 1081BASIC RES CARDIOL0300-84283292 5.904 5.362 1.16772 6390NEUROTHERAPEUTICS1933-72131923 5.904 5.720.90563 381ALLERGY0105-453812173 5.883 5.983 1.58193 4422J CELL SCI0021-953340261 5.877 6.375 1.032535 1391BREAST CANCER RES1465-542X7547 5.872 6.2640.82172 1528CARBON0008-622332742 5.868 6.35 1.197674 2915FISH FISH1467-29601846 5.8557.326 1.53826 1699CHEST0012-369244596 5.854 6.42 3.394307 4871J INFECT DIS0022-189942783 5.848 5.914 1.556493 2189CURR OPIN LIPIDOL0957-96723620 5.839 5.7380.92264 6966PIGM CELL MELANOMA R1755-14713385 5.839 5.434 1.39768 1685CHEM-EUR J0947-653960788 5.831 5.623 1.2411916 717APPL CATAL B-ENVIRON0926-337323011 5.825 6.0310.965480 4486J CLIN PSYCHIAT0160-668917639 5.812 5.6390.726157 1765CIRC-CARDIOVASC IMAG1941-96511650 5.795 6.579 1.17984 5924MAYO CLIN PROC0025-61969444 5.79 5.638 1.44109 4413J CATAL0021-951734516 5.787 6.249 1.025284 5164J NUCL MED0161-550521262 5.774 6.4020.934243 2597ENVIRON MICROBIOL1462-291213228 5.756 5.943 1.455242 2626EPIDEMIOLOGY1044-39838979 5.738 6.241 2.12588 8328WIRES COMPUT MOL SCI1759-0876570 5.738 5.738 3.51856 2539ENDOSCOPY0013-726X8401 5.735 5.355 1.514144 4048INT REV IMMUNOL0883-******* 5.733 4.140.44829 324AGING CELL1474-97184134 5.705 6.415 1.485130 2885FASEB J0892-663839540 5.704 6.222 1.13462 1895COCHRANE DB SYST REV1469-493X34230 5.703 6.5120.728977 5027J MED GENET0022-259311563 5.703 5.793 1.353116 5687LAB CHIP1473-019716485 5.697 6.136 1.256617 510ANAL CHEM0003-270096794 5.695 5.7690.9481479 6697P ROY SOC B-BIOL SCI0962-845237539 5.683 5.832 1.224624 8330WIRES NANOMED NANOBI1939-5116983 5.681 6.34 1.08547 1767CIRC-CARDIOVASC QUAL1941-77051551 5.658 5.647 1.43100 7369RETROVIROLOGY1742-46903084 5.657 4.857 1.505107 6713PAIN0304-395929370 5.644 6.125 1.264269 3917INT J NEUROPSYCHOPH1461-14574003 5.641 5.0920.805123 1530CARCINOGENESIS0143-333421223 5.635 5.5570.9553106383NEUROSCIENTIST1073-85843259 5.633 6.417 1.35645 7327RENEW SUST ENERG REV1364-032110347 5.627 6.5770.803584 6321NEUROBIOL DIS0969-996111288 5.624 5.482 1.493296 5925MBIO2150-75111260 5.621 5.621 1.536151 4817J HIGH ENERGY PHYS1126-670852898 5.618 4.712 2.6581861 1589CELL MOL LIFE SCI1420-682X17974 5.615 6.359 1.072290 5022J MED CHEM0022-262359227 5.614 5.383 1.225890 1362BRAIN BEHAV IMMUN0889-15916137 5.612 5.698 1.082147 6124MOL CANCER THER1535-716314654 5.599 5.72 1.201259 1873CLIN REV ALLERG IMMU1080-05491685 5.59 3.955 1.30662 7194PSYCHOL MED0033-291716680 5.587 6.1480.913230 2098CRIT REV BIOCHEM MOL1040-92382729 5.5788.032 1.23330 6583OPHTHALMOLOGY0161-642026007 5.563 5.777 1.065354 3107GENET MED1098-36004119 5.56 5.035 1.554121 1259BIOTECHNOL BIOFUELS1754-6834903 5.552 6.4590.35288 2401DRUG METAB REV0360-25322342 5.538 5.843 1.2516 291ADV SYNTH CATAL1615-415015502 5.535 5.323 1.109404 5793MACROMOLECULES0024-929797921 5.521 5.209 1.0941069 6176MON NOT R ASTRON SOC0035-871196083 5.521 5.009 1.7942574 4853J IMMUNOL0022-1767129339 5.52 5.6730.951289 7791SPACE SCI REV0038-63087134 5.519 5.1060.921114 8135TRENDS PARASITOL1471-49224819 5.513 4.878 1.11470 943ATMOS CHEM PHYS1680-731622919 5.51 5.556 1.176723 3765INT J CARDIOL0167-527312371 5.509 4.125 1.681326 2133CSH PERSPECT MED2157-1422211 5.5 5.5 1.099142 6511NUTR RES REV0954-******** 5.5 5.2020.11817 3323HIPPOCAMPUS1050-96318046 5.492 5.484 1.603184 2798EUROSURVEILLANCE1560-79175236 5.491 1.34188 3492IEEE T FUZZY SYST1063-67066237 5.484 4.8850.58193 6155MOL NEUROBIOL0893-******** 5.471 5.5350.782101 6289NEOPLASIA1522-80025715 5.47 5.077 1.208120 4096INVEST RADIOL0020-99965353 5.46 4.444 1.392102 1090BBA-GENE REGUL MECH1874-93994518 5.456 4.338 1.217129 2201CURR OPIN PHARMACOL1471-48925198 5.443 6.4470.765102 50ACS CHEM BIOL1554-89293417 5.442 5.478 1.387230 2206CURR OPIN SOLID ST M1359-02862508 5.4387.3290.91323 1248BIOSENS BIOELECTRON0956-566322068 5.437 5.389 1.105448 4592J ECOL0022-047713938 5.431 6.199**** ****BIOESSAYS0265-92478695 5.423 4.814 1.291134 4448J CHILD PSYCHOL PSYC0021-963012841 5.422 6.2350.976127 2194CURR OPIN NEUROL1350-75404449 5.416 5.0350.80497 4427J CEREBR BLOOD F MET0271-678X14671 5.398 5.66 1.093194 4439J CHEM THEORY COMPUT1549-961811067 5.389 5.936 1.067507 7655SEMIN IMMUNOPATHOL1863-22971214 5.379 5.668 1.6958 6128MOL CELL BIOL0270-730667211 5.372 5.745 1.036415 1200BIOMACROMOLECULES1525-779724209 5.371 5.750.721480 4261J ANTIMICROB CHEMOTH0305-745320364 5.338 4.686 1.257428 4466J CLIN EPIDEMIOL0895-435615399 5.332 5.120.711149 5284J PHYS G NUCL PARTIC0954-******** 5.326 2.812 1.37184 1165BIOINFORMATICS1367-480351753 5.323 6.9110.729728 3052FUNGAL DIVERS1560-27451665 5.319 4.2 1.73653 6993PLANT MOL BIOL REP0735-******** 5.319 4.020.293157 2152CURR GENE THER1566-52321362 5.318 4.3220.6141 4224J AM MED DIR ASSOC1525-86102480 5.302 3.912 1.3431781398BRIEF BIOINFORM1467-54633073 5.2987.51 1.27658 426AM J KIDNEY DIS0272-638619101 5.294 5.417 1.724199 2813EXERC SPORT SCI REV0091-63312207 5.283 4.841127 5781MABS-AUSTIN1942-0862765 5.275 4.8240.78565 3012FREE RADICAL BIO MED0891-584931156 5.271 5.969 1.033450 49ACS CATAL2155-54351461 5.265 5.265 1.222315 2533ENDOCR-RELAT CANCER1351-00884611 5.261 5.1720.73494 6224NANOMEDICINE-UK1743-58892713 5.26 6.2360.746114 4068INTENS CARE MED0342-464214780 5.258 5.036 1.074215 2611ENVIRON SCI TECHNOL0013-936X92385 5.257 5.8650.7921608 4364J BIOMED NANOTECHNOL1550-70332198 5.256 4.366 1.491108 6110MODERN PATHOL0893-395210184 5.253 5.058 1.371175 224ADV CATAL0360-05641399 5.25 5.28602 226ADV CHEM PHYS0065-23852306 5.25 4.250.71746 1066B WORLD HEALTH ORGAN0042-968611151 5.25 6.076 1.04295 2708EUR J HEART FAIL1388-98425824 5.247 4.738 1.469147 2770EUR PHYS J C1434-604411003 5.247 3.603 2.222406 1576CELL CYCLE1538-410115668 5.243 4.806 1.079444 4679J EXP BOT0022-095724541 5.242 5.5420.903493 7814SPORTS MED0112-16427069 5.237 5.7550.64164 3202GLOBAL ENVIRON CHANG0959-37804587 5.236 6.9010.88285 7047POLYM CHEM-UK1759-99543328 5.231 5.231 1.305397 3018FRONT AGING NEUROSCI1663-4365392 5.224 5.1690.72733 3933INT J OBESITY0307-056518052 5.221 5.522 1.174213 852ARCH TOXICOL0340-57614824 5.215 3.990.94149 3376HUM MUTAT1059-779411082 5.213 5.761 1.754224 3077GASTROINTEST ENDOSC0016-510718497 5.21 5.276 2.32297 1524CANCER-AM CANCER SOC0008-543X62757 5.201 5.693 1.108674 2205CURR OPIN RHEUMATOL1040-87113701 5.191 4.256 1.04589 1688CHEMCATCHEM1867-38802718 5.181 5.3070.941255 2315DIABETES OBES METAB1462-89024587 5.181 4.415 1.491173 2463ECOLOGY0012-965850217 5.175 6.3720.583283 3497IEEE T IND ELECTRON0278-004617404 5.165 5.0780.943470 528ANESTHESIOLOGY0003-302222547 5.163 5.302 1.959219 5065J MOL CELL CARDIOL0022-282811674 5.148 5.034 1.478232 7200PSYCHONEUROENDOCRINO0306-45309603 5.137 5.926 1.091198 6978PLANT CELL ENVIRON0140-779114009 5.135 5.861 1.639158 6122MOL CANCER1476-45984995 5.134 5.0970.3686 6849PHARMACOGENOMICS J1470-269X2084 5.134 4.455 1.12365 2444ECOGRAPHY0906-******** 5.124 5.7910.925120 2179CURR OPIN DRUG DISC1367-67331825 5.121 4.1080 3657INFLAMM BOWEL DIS1078-09988279 5.119 5.233 1.161261 6801PEDIATRICS0031-400559035 5.119 5.930.951687 2702EUR J EPIDEMIOL0393-******** 5.118 4.1160.49489 2729EUR J NUCL MED MOL I1619-707010881 5.114 4.821 1.202198 4805J HEART LUNG TRANSPL1053-24987139 5.112 3.6270.975159 5104J NATL COMPR CANC NE1540-14051890 5.1120.522115 7318REMOTE SENS ENVIRON0034-425724105 5.103 6.1440.987388 7724SLEEP0161-810514444 5.1 6.175 1.068162 2099CRIT REV BIOTECHNOL0738-******** 5.095 5.9660.95221 604ANN MED0785-38903665 5.094 4.640.76397 74ACTA BIOMATER1742-706110169 5.093 5.3780.903453 1575CELL COMMUN SIGNAL1478-811X520 5.0930.20539 7499RNA1355-838211854 5.088 5.43 1.01201920ASTRON ASTROPHYS0004-6361101305 5.084 4.422 1.4511892 1404BRIT J CANCER0007-092038414 5.082 5.2060.827561 5569J VIROL0022-538X93028 5.076 4.893 1.2581559 1831CLIN J AM SOC NEPHRO1555-90418449 5.068 5.445 1.1240 1415BRIT J PHARMACOL0007-118828119 5.067 4.898 1.288539 3198GLIA0894-149110371 5.066 5.406 1.38166 2105CRIT REV MICROBIOL1040-841X1335 5.065 5.615 1.09521 2675EUR HEART J SUPPL1520-765X977 5.065 1.817 1.910 2681EUR J CANCER0959-804921316 5.061 5.2570.991343 208ADV AGRON0065-21132753 5.06 5.5120.45824 5336J PROTEOME RES1535-389317943 5.056 5.2230.882544 3916INT J NEURAL SYST0129-0657992 5.054 3.6460.45735 1975COMPR REV FOOD SCI F1541-43371046 5.053 4.7920.26730 3273HEART RHYTHM1547-52717449 5.045 4.719 2.089237 1775CLADISTICS0748-30073315 5.043 6.183 1.86730 7737SOC COGN AFFECT NEUR1749-50161980 5.042 6.78 1.347101 3173GEOSCI MODEL DEV1991-959X626 5.03 4.50.84691 6186MRS BULL0883-******** 5.024 5.590.569116 3269HEART1355-603713857 5.014 4.769 1.667243 48ACS APPL MATER INTER1944-82448635 5.008 5.040.683953 2491ELECTROANAL CHEM0070-977837757.50.254 216ADV APPL MICROBIOL0065-21641233 4.974 4.7840.33321 4045INT REV CEL MOL BIO1937-6448825 4.973 4.9440.40849 2713EUR J IMMUNOL0014-298020974 4.97 4.7680.739322 663ANNU REV ENV RESOUR1543-59381402 4.9687.25018 923ASTRON J0004-625634668 4.965 4.571 1.162334 6154MOL MICROBIOL0950-382X37172 4.961 5.099 1.123359 2351DIS MODEL MECH1754-84031212 4.959 5.0090.98988 1407BRIT J HAEMATOL0007-104820668 4.942 4.7260.891266 4497J COMB CHEM1520-47662925 4.933 3.1020 5789MACROMOL RAPID COMM1022-133612103 4.929 4.6180.916261 5129J NEUROL NEUROSUR PS0022-305023923 4.924 5.144 1.69187 2628EPIGENETICS-US1559-22942289 4.92 4.8810.773150 4050INT REV PHYS CHEM0144-235X1524 4.92 5.595 2.23113 1119BEST PRACT RES CL EN1521-690X2576 4.912 5.1810.25866 1091BBA-MOL BASIS DIS0925-44396277 4.91 4.932 1.248202 5451J STAT SOFTW1548-76602629 4.91 5.9070.75377 5356J R SOC INTERFACE1742-56895016 4.907 5.1650.806320 4206J AM ACAD DERMATOL0190-962219760 4.906 4.5150.896280 1518CANCER PREV RES1940-62073114 4.891 5.126 1.401142 2187CURR OPIN INFECT DIS0951-******** 4.87 4.610.83987 2846EXPERT OPIN DRUG DEL1742-52472829 4.869 5.1330.495103 469AM J SURG PATHOL0147-518516422 4.868 4.8570.798223 7021PLOS COMPUT BIOL1553-735811758 4.867 5.9390.824507 6837PFLUG ARCH EUR J PHY0031-67689307 4.866 3.9280.853129 2810EVOLUTION0014-382030585 4.864 5.4020.939313 4347J BIOGEOGR0305-027010682 4.863 4.979 1.399183 3042FUNCT ECOL0269-84639681 4.861 5.3930.882153 2231CURR TOP MICROBIOL0070-217X4958 4.86 4.744 5.05319 1875CLIN SCI0143-52218069 4.859 4.843 1.2110 174ACTA PSYCHIAT SCAND0001-690X11048 4.857 4.625198 386ALTERN MED REV1089-51591288 4.857 5.0340.56 250ADV GENET0065-26601198 4.85 4.102010 4253J ANIM ECOL0021-879012354 4.841 5.1660.881134。